A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia

• Sumithira Vasu,
• Jessica K. Altman,
• Geoffrey L. Uy,
• Martin S. Tallman,
• Ivana Gojo,
• Gerard Lozanski,
• Ute Burkard,
• Annika Osswald,
• Pamela James,
• Björn Rüter,
• William Blum

Affiliations

Sumithira Vasu

Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

Jessica K. Altman

Division of Hematology/Oncology, Northwestern University, Chicago, Illinois

Geoffrey L. Uy

Washington University School of Medicine, Siteman Cancer Center, St Louis, MO

Martin S. Tallman

Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY

Ivana Gojo

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD

Gerard Lozanski

Department of Pathology, The Ohio State University, Columbus, OH

Ute Burkard

Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß

Annika Osswald

Boehringer Ingelheim Pharma GmbH and Co. KG, Biberach an der Riß

Pamela James

Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT

Björn Rüter

Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT

William Blum

Department of Hematology and Medical Oncology, Emory University School of Medicine, Winship Cancer Institute, Atlanta, GA